Safety study of 23-valent pneumococcal polysaccharide vaccine in Hebei Province
10.3969/j.issn.1006-2483.2024.03.003
- VernacularTitle:河北省23价肺炎球菌多糖疫苗安全性分析
- Author:
Li SUN
1
;
Yanli CONG
1
;
Shiheng CUI
1
;
Jing LI
1
;
Yihan WANG
1
;
Yafei WANG
1
;
Shifan WANG
1
;
Yu GUO
1
Author Information
1. Hebei Provincial Center for Disease Control and Prevention , Shijiazhuang , Hebei 050021 ,China
- Publication Type:Journal Article
- Keywords:
23-valent pneumococcal polysaccharide vaccine;
Adverse events following immunization;
Passive surveillance
- From:
Journal of Public Health and Preventive Medicine
2024;35(3):10-13
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the occurrence characteristics of adverse events following immunization (AEFI) of 23-valent pneumococcal polysaccharide vaccine (PPSV-23) in Hebei Province and to evaluate the safety of the vaccine. Methods AEFI cases related to vaccination of PPSV-23 in Hebei Province from January 1, 2020 to December 31, 2022 were collected through the AEFI surveillance module of Chinese Center for Disease Control and Prevention Information System. The incidence of reported AEFI cases were then analyzed and compared. Results The reported incidence rate of AEFI of PPSV-23 was 56.12 /100,000 doses, and the incidence rate of adverse reactions was 55.50 /100 000 doses. The incidence rate of common adverse reactions was 53.94/100 000 doses, and the incidence rate of rare adverse reactions was 1.56/100 000 doses. Most of the reported AEFI cases caused by PPSV-23 were common adverse reactions, which occurred mainly within one day after vaccination, and the overall regression was positive. Conclusion The 23-valent pneumococcal polysaccharide vaccine used in Hebei Province is safe，but its safety monitoring still needs to be strengthened.
